Strongest evidence (moderate strength):
- Liver enzymes: 5 studies (3 beneficial, 2 neutral) showed a small reduction in AST levels in NAFLD/MASLD patients at 298–1000 IU/day; 4 studies (all beneficial, 3 statistically significant) showed small-to-moderate reductions in ALT at 400–1000 IU/day. Effects were typically seen after 8–12 weeks.
- Pain reduction: 3 studies (all beneficial, predominantly small effects) in conditions like fibromyalgia, carpal tunnel syndrome, and oral mucosal diseases. Most used vitamin E in combination with other nutrients, limiting isolation of its specific effect.
- Inflammation reduction: 3 studies (all beneficial, mixed effect sizes) in clinical populations (gastrointestinal surgery, sarcopenia, NAFLD/NASH). The most studied dose was 335 mg/day.
Mixed or weaker evidence (low strength):
- TNF-α reduction: 1 beneficial (small effect) out of 3 RCTs, with 2 neutral. Effect may be population-dependent (benefit seen in NASH but not in hemodialysis or sarcopenia).
- Vitamin E levels: 1 beneficial (moderate effect in vitiligo patients) out of 3 meta-analyses; 2 neutral. Inconsistent and small evidence base.
- Sperm morphology: 1 beneficial (moderate effect, 100 mg three times/day for 90 days) out of 3 studies; 2 neutral. Overall mixed.
- Sperm motility: 0 beneficial out of 3 studies; all neutral. No evidence that vitamin E alone improves motility.
- Malondialdehyde (MDA) levels: 1 beneficial (large effect in epilepsy patients from a meta-analysis) out of 3 studies; 2 neutral (small effects in MASLD and infertile men). Population-specific benefit possible.
Effective dose patterns:
For liver outcomes, doses converged around 298–1000 IU/day, with most effects observed at 400–1000 IU/day. Pain and inflammation studies used similar ranges (e.g., 335 mg/day, 400–800 IU/day). For sperm morphology, the only beneficial study used 300 mg/day (100 mg three times daily). No clear dose emerged for TNF-α, MDA, or vitamin E levels.
Population insights:
The strongest and most consistent effects appear in people with NAFLD/MASLD. Pain and inflammation benefits were seen in diverse clinical populations (fibromyalgia, postsurgical, sarcopenia). Several outcomes were studied exclusively or primarily in clinical groups, so findings may not generalize to healthy individuals.
Notable caveats:
- Most evidence syntheses include only 3–5 studies, making conclusions preliminary.
- Publication bias is likely for ALT, pain, and inflammation outcomes (overwhelmingly positive studies).
- Many studies used vitamin E in combination with other supplements, making it difficult to attribute effects solely to vitamin E.
- Several studies failed to reach statistical significance, suggesting true effect sizes may be smaller than the predominant direction indicates.